Pulike Biological Engineering, Inc. (SHA:603566)

Market Cap	3.74B -20.9%
Revenue (ttm)	1.06B -2.3%
Net Income	172.82M +46.0%
EPS	0.50 +44.4%
Shares Out	341.92M
PE Ratio	21.81
Forward PE	21.86
Dividend	0.60 (5.49%)
Ex-Dividend Date	Oct 17, 2025

Volume	3,464,710
Open	10.88
Previous Close	10.93
Day's Range	10.67 - 11.00
52-Week Range	10.39 - 15.79
Beta	0.44
Analysts	Strong Buy
Price Target	15.44 (+43.76%)
Earnings Date	Aug 28, 2026

About SHA:603566

Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 1,551
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603566

Financial Performance

In 2025, SHA:603566's revenue was 1.09 billion, an increase of 4.54% compared to the previous year's 1.04 billion. Earnings were 184.99 million, an increase of 99.33%.